KDIGO 2017 CLINICAL PRACTICE GUIDELINE ON THE PREVENTION, DIAGNOSIS, EVALUATION AND TREATMENT OF HEPATITIS C IN CKD
Hepatitis C virus (HCV) infection remains a serious worldwide public health problem. Some 170–200 million individuals remain chronically infected with HCV and HCV infection is both a cause and a complication of chronic kidney disease (CKD). In 2008, KDIGO published its first guideline on HCV in CKD which undoubtedly contributed to improving the understanding and management of HCV by nephrologists and hepatologists. In the last several years, revolutionary progress has been achieved in the area of HCV treatment, thus warranting a complete guideline systematic review on literature published since 2008.
KDIGO has a long history of developing and implementing high quality and informative nephrology guidelines for clinicians to assist in their decision making. Consistent with our goal in keeping all of our guidelines current and up-to-date, KDIGO has now developed a brand new global, evidence-based Clinical Practice Guideline on the Prevention, Diagnosis, Evaluation and Treatment of HCV in CKD. This guideline will assist health professionals in detecting and evaluating HCV in CKD; optimizing the management and treatment of HCV in CKD patients and in patients before and after kidney transplantation; preventing HCV transmission in dialysis units; and providing guidance on the management of kidney diseases caused by HCV.
The public review period has now closed.
Please note that by agreeing to provide feedback on this draft guideline document, you hereby permit KDIGO to acknowledge your participation as a reviewer in the final publication.